Molecular and clinical correlates of high FOLH1 (PSMA) RNA expression in primary and metastatic prostate cancer.

ABSTRACT:

Background

Prostate-specific membrane antigen (PSMA; FOLH1) is a cell-surface target for diagnostics and treatment in prostate cancer. We utilized a database of molecularly-profiled prostate tumors to evaluate clinical, genomic, and immunologic correlates of high FOLH1 RNA expression.

Patients and methods

Prostate cancer specimens (N = 7,082) underwent DNA/RNA sequencing and immunohistochemistry at Caris Life Sciences. FOLH1-High/Low expression was defined by upper/lower quartiles or median transcripts per million. Overall survival (OS) was calculated from insurance claims.

Results

Prostate adenocarcinoma had 2.97-fold higher FOLH1 expression compared to high-grade neuroendocrine prostate cancer (q < 0.0001). Of 7,020 adenocarcinomas, 4,464 were primary prostate sampl

SUBMITTER: McKay RR 

PROVIDER: S-EPMC12609168 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature